Kedrion and Nabi Biopharmaceuticals announce initiation of Civacir® phase II “proof-of-concept” clinical trial
Nabi (a biopharmaceutical company based in Florida) announced today that it has initiated in the USA, further to the agreement signed with Kedrion, its Phase II “proof-of-concept” clinical trial for Civacir® [epatitis C human immune globulin]. Civacir®, when approved, would be the first therapy for the prevention of the recurrence of hepatitis C-related liver disease
Kedrion and ProMetic form strategic alliance to develop Orphan Drugs from plasma
Kedrion S.p.A. and ProMetic BioTherapeutics, Inc., a subsidiary of ProMetic Life Sciences Inc. (TSX: PLI) (“ProMetic”) have formed a strategic alliance to develop orphan drugs derived from human plasma utilizing ProMetic’s proprietary manufacturing process, the Plasma Protein Purification System (PPPS). The alliance between the two companies was created to select specific proteins which can be
Plasma system, exporting the Italian “Contract Manufacturing” model to Chile
“Teamwork to improve plasma quality in Chile” is based on an agreement made in November 2005 by the Ministry of Health in Chile and SIMTI (Italian Transfusion Medicine and Immunohaematology Company), which marked the operational meeting between the Chilean delegation specially flown in to Italy and the CNR (National Research Council), SIMTI, Tuscany’s CRCC (Regional
Plasma derivates: reinforcing Tuscany as leader in the Balkans
Kedrion Biopharmaceuticals has won a contract to supply FIX in Bosnia. This is the plasma-derived drug used in the treatment of Haemophilia B (incidence of 1 in 60,000 people) which has a world market worth 200 million US dollars, with production of 430 million international units and distribution of 42% in Europe, 24% in North
“Von Willebrand Disease”: simple handbook for haemophilia centres, patients and their families
Answers to the questions most frequently asked by patients about causes, symptoms and treatments. A personal card that we recommend you to carry with you at all times. A monthly diary with annual summary. “Von Willebrand Disease – complex but not complicated (if you know about it)” is the title of the handbook which has
Plasmaderivatives: “Investitori Associati” invests in the sector with a 40% share in leading company Kedrion
Investitori Associati SGR, the common fund management company for closed-end security investment, is investing in the plasmaderivatives sector with a 40% share in Kedrion SpA, the leading company in Italy in this area. It belongs to the Marcucci family who will retain the majority holding with 60% of the shares. The operation, financed by Banca
First Russian factory plasma-derived products of internal standard to be set up with Kedrion technology
Kedrion, the leading biopharmaceutical company in the haemoderivatives sector whose principal headquarters is in Tuscany, is to set up a technology exchange in Russia. In 2006, in Kirov in the Volga region, work will begin to set up the first Russian factory producing international standard plasma-derived products. The factory, which will be fully operating by
